ConductScience.org, home

Paper36449413

Lecanemab in Early Alzheimer's Disease.

van Dyck CH and 18 others. N Engl J Med, 2023. Cited by 4,639 papers, by iCite.

Cite this record

ConductScience Library. Lecanemab in Early Alzheimer's Disease. Papers, record 36449413. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36449413

Download JSON
Disease
Alzheimer disease441 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lecanemab in Early Alzheimer's Disease.
PubMed
Journal
N Engl J Med
PubMed
Year
2023
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
4,639
iCite
Relative citation ratio, by iCite
623
iCite
Revised in PubMed
2025-06-26
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1van Dyck CHChristopher H
2Swanson CJChad J
3Aisen PPaul
4Bateman RJRandall J
5Chen CChristopher
6Gee MMichelle
7Kanekiyo MMichio
8Li DDavid
9Reyderman LLarisa
10Cohen SSharon
11Froelich LLutz
12Katayama SSadao
13Sabbagh MMarwan
14Vellas BBruno
15Watson DDavid
16Dhadda SShobha
17Irizarry MMichael
18Kramer LDLynn D
19Iwatsubo TTakeshi

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
Nootropic AgentsMajor topic
Humans
Activities of Daily Living
Amyloid beta-Peptides
Cognition
Double-Blind Method

Source PubMed

Download CSV of topics

Trials10

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseDerived from the trialYesClinicalTrials.gov
NCT05882344Cholinergic Deep Brain Stimulation for Alzheimer's DiseaseBackgroundClinicalTrials.gov
NCT06362707Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)BackgroundClinicalTrials.gov
NCT06384573DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's DiseaseBackgroundClinicalTrials.gov
NCT06470061RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-βBackgroundClinicalTrials.gov
NCT06638632Decision Aid for Anti-Amyloid TherapyBackgroundClinicalTrials.gov
NCT06868030Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational StudyBackgroundClinicalTrials.gov
NCT07299344A Model for Continuous Care of Fragile PatientsBackgroundClinicalTrials.gov
NCT07667478NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASEBackgroundClinicalTrials.gov
NCT07680660Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's DiseaseBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections14

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in36456815Heralded Alzheimer's drug works - but safety concerns loom.https://conductscience.org/library/papers/36456815PubMed
Comment in36599061Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.https://conductscience.org/library/papers/36599061PubMed
Comment in36599066Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.https://conductscience.org/library/papers/36599066PubMed
Comment in36599073Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.https://conductscience.org/library/papers/36599073PubMed
Comment in36609712Lecanemab trial in AD brings hope but requires greater clarity.https://conductscience.org/library/papers/36609712PubMed
Comment in36627422FDA approves Alzheimer's drug lecanemab amid safety concerns.https://conductscience.org/library/papers/36627422PubMed
Comment in36781970Drug trial for Alzheimer's disease is a game changer.https://conductscience.org/library/papers/36781970PubMed
Comment in36869178FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective.https://conductscience.org/library/papers/36869178PubMed
Comment in37081342Neuer Antikörper bremst kognitiven Verfall.https://conductscience.org/library/papers/37081342PubMed
Comment in37099351Lecanemab in Early Alzheimer's Disease.https://conductscience.org/library/papers/37099351PubMed
Comment in37099352Lecanemab in Early Alzheimer's Disease.https://conductscience.org/library/papers/37099352PubMed
Comment in37099353Lecanemab in Early Alzheimer's Disease.https://conductscience.org/library/papers/37099353PubMed
Comment in37099354Lecanemab in Early Alzheimer's Disease.https://conductscience.org/library/papers/37099354PubMed
Comment in37099355Lecanemab in Early Alzheimer's Disease. Reply.https://conductscience.org/library/papers/37099355PubMed

Download CSV of comments and corrections

Cited by3,459

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4,639 citations.

PMIDTitleJournalYearIn PapersSource
42988979Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease.Neurol Sci2026https://conductscience.org/library/papers/42988979PubMed
42985795Deep Learning for AD Risk Screening and Progression Prediction.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42985795PubMed
42985466Alzheimer's Disease: Mechanisms and Therapeutic Advances.MedComm (2020)2026https://conductscience.org/library/papers/42985466PubMed
42984124Intrathecal Transplantation of Human Umbilical Cord-Derived MSCs Outperforms Intravenous Administration in Attenuating Pathology and Cognitive Deficits in Alzheimer's Disease Mice.CNS Neurosci Ther2026https://conductscience.org/library/papers/42984124PubMed
42982982Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan.J Hum Genet2026https://conductscience.org/library/papers/42982982PubMed
42982811Physiological APP processing is required for synaptic plasticity and cognition.Cell Death Dis2026https://conductscience.org/library/papers/42982811PubMed
42980730From molecular pathways to nanocarrier design: a translational framework for lipid-based nanoparticles in Alzheimer's disease.Discov Nano2026https://conductscience.org/library/papers/42980730PubMed
42978683Integrated computational screening and biochemical validation identify natural small molecules targeting Aβ aggregation and dissociation.J Pharm Pharm Sci2026https://conductscience.org/library/papers/42978683PubMed
42969459Navigating the Challenges of Shared Decision-Making in Amyloid Immunotherapy for Alzheimer's Disease.Eur J Neurol2026https://conductscience.org/library/papers/42969459PubMed
42968820Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026.Clin Interv Aging2026https://conductscience.org/library/papers/42968820PubMed
42967498Measuring mild cognitive impairment using routinely collected health-care data: A conceptual framework and guidance for embedded pragmatic clinical trials.Alzheimers Dement2026https://conductscience.org/library/papers/42967498PubMed
42963333Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials.Alzheimers Dement2026https://conductscience.org/library/papers/42963333PubMed
42961631Cost-Effectiveness Analysis of Disease-Modifying Therapies for Early Alzheimer's Disease in China.Neurol Ther2026https://conductscience.org/library/papers/42961631PubMed
42960521The Association of Amyloid-β and Tau With Synaptic Dysfunction in Alzheimer's Disease.Ann Clin Transl Neurol2026https://conductscience.org/library/papers/42960521PubMed
42959393Differences in anti-amyloid therapy eligibility assessment based on use of the SWI versus GRE sequence.Alzheimers Dement (Amst)2026https://conductscience.org/library/papers/42959393PubMed
42957970APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition.Alzheimers Dement2026https://conductscience.org/library/papers/42957970PubMed
42953588TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges.Drug Des Devel Ther2026https://conductscience.org/library/papers/42953588PubMed
42952982Peripheral serum copper metabolite levels measured by ultrafiltration aid in the clinical screening of Alzheimer's disease.Front Psychiatry2026https://conductscience.org/library/papers/42952982PubMed
42951866Evaluating the Association Between PPI Use and Dementia Risk Considering Methodological Choices: An Updated Meta-Analysis.Clin Pharmacol Ther2026https://conductscience.org/library/papers/42951866PubMed
42948157Heterogeneous progression of AT(N) biomarkers in data-driven subtypes of Alzheimer's disease.Front Aging Neurosci2026https://conductscience.org/library/papers/42948157PubMed

See all 3,459 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
APP351PubTator's text mininghttps://conductscience.org/library/genes/351

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
LECANEMABCHEMBL3833321Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3833321

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36449413

GET https://conductscience.org/api/papers/v1/36449413/cited_by?page=2